Tesamorelin

Overview

What is Tesamorelin?

Tesamorelin is a growth hormone releasing hormone analogue approved as Egrifta for reducing excess abdominal fat in people with HIV associated lipodystrophy. Its entire trial record sits in that population rather than in general body composition use.

• Visceral Fat
• Body Composition
• GH Support
• Metabolic Health

What the research reports

Reported benefits of Tesamorelin

Outcomes described across the published Tesamorelin literature and ongoing study. Read each as research context, not a promised result.

1. 01

   Visceral fat reduction study

   Pooled phase 3 data reported visceral adipose tissue down 24 percent at 26 weeks, with the reduction sustained through 52 weeks in the same patient cohort.

2. 02

   Liver enzyme study outcome

   A 2017 analysis found patients who responded with visceral fat loss also showed greater reductions in ALT and AST liver enzymes. Reported in research settings.

3. 03

   Lipid profile change study

   Trials reported improved triglycerides and cholesterol alongside the fat reduction, without a meaningful change in insulin response. Reported in research settings.

4. 04

   Inflammatory marker shift

   A 2011 trial reported lower fibrinolytic markers and improved adiponectin in parallel with the loss of visceral fat. Described in the research record.

5. 05

   Physiological GH stimulation

   Acts as a GHRH analogue on the pituitary, producing a pulsatile release pattern rather than replacing growth hormone directly. Reported in research settings.

Dosage and protocol

Tesamorelin dosage and protocol

The approved protocol is 2 mg once daily by subcutaneous injection across 12 to 26 weeks. The half-life is 26 to 38 minutes. Figures describe study protocols, not a personal regimen.

Route

Subcutaneous injection

Example range

2 mg

Frequency

Once daily

Timing

Once daily, morning or before bed. Use within about three days.

Clinical evidence

Clinical evidence for Tesamorelin

The published record for Tesamorelin, labeled by strength so you can see what is settled and what is emerging.

Interactions

How it pairs with other peptides

Ipamorelin

Both raise growth hormone by different routes, so combining increases total IGF-1 exposure.

Sermorelin

Both are GHRH analogues targeting the same receptor, so combining duplicates a single mechanism.

Insulin therapy

Growth hormone raises blood glucose, so glycaemic control may need review during treatment.

Corticosteroids

Steroids can blunt the growth hormone response, reducing the effect seen in trial conditions.